Merck & Co., Inc. is 70.4x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($294.13 B vs $4.18 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | DNTH | MRK |
|---|---|---|
| Market cap | $4.18 B | $294.13 B |
| US-listed rank | #1530 | #44 |
| Revenue (latest FY) | $2.04M | $65.01B |
| Net income (latest FY) | -$162.34M | $18.25B |
| Net margin | -7973.3% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 624 | 996 |
Merck & Co., Inc. is 70.4x more valuable than Dianthus Therapeutics, Inc. /DE/ by market capitalization ($294.13 B vs $4.18 B).
In their latest fiscal years, Dianthus Therapeutics, Inc. /DE/ reported $2.04M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Dianthus Therapeutics, Inc. /DE/ and Merck & Co., Inc., or browse the full rankings.